Whitehawk Therapeutics presented data showing that MUC16 expression remains high and stable in ovarian cancer patients after standard treatments, making it a durable target for antibody drug conjugates (ADCs). High MUC16 levels were linked to poorer survival in high-grade serous ovarian carcinoma, the most common subtype. These findings support the ongoing Phase 1 trial of HWK-016, a MUC16-directed ADC, for advanced ovarian and endometrial cancers, highlighting its potential in combination therapies and relapsed cases.
Whitehawk Therapeutics' presentation on MUC16 as a durable ADC target in ovarian cancer is noted alongside Pluang's health-sector market data as of Oct 01, 2026 17:52 WIB. Of 100 priced US health-sector stocks tradable on Pluang, 42 rose and 46 fell today. Notable movers include Alcon AG (ALC) at USD 63.88 with a -1.34% change and 100% buy order activity, Smith & Nephew plc (SNN) at USD 26.60 with a -1.34% change, and Abeona Therapeutics Inc (ABEO) at USD 5.18 with a -1.33% change. The most notable figure is Alcon AG's full buy order activity on Pluang.
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
PNC Financial Services Group received mixed analyst ratings on October 1, 2026. Evercore ISI maintained an Outperform rating but lowered its price target to $265 from $285, citing strong net interest income growth but caution on expenses and asset qu...
Accenture reported fiscal Q4 2026 earnings that exceeded analyst expectations with EPS of $3.29, up 46% year-over-year, and revenue of $18.68 billion, a 6% increase. The company also saw a 4% rise in new bookings to $22.17 billion, reflecting strong ...
Analysts have downgraded PepsiCo and lowered its price targets due to weak stock performance and sales challenges in its Frito-Lay North America segment. Despite efforts to improve products, sales remain sluggish, raising concerns about PepsiCo's ope...
